F-1/A: MEDI Group Files F-1/A for Nasdaq IPO Amid Revenue Decline

Sentiment:

IPO Registration Statement Amendment 4 September 2025 9:49 PM

MEDI Group Limited, a Hong Kong-based medical cosmetology and beauty service provider, filed an amended F-1 registration statement for its initial public offering on Nasdaq, seeking to raise $15 million despite recent revenue declines and going concern doubts.

Capital raiseThe company is undertaking an initial public offering (IPO) to sell up to 3,333,333 Class A Ordinary Shares, aiming to raise $15,000,000 in gross proceeds.Net proceeds from the IPO are estimated to be $12,260,000 (without over-allotment) or $14,400,000 (with full over-allotment).The proceeds are intended for R&D capacity (5%), market expansion (25%), general working capital (65%), and advisory fee payment (5%).The company has historically relied on bank borrowings and shareholder loans for working capital and intends to continue relying on debt and equity financing until positive cash flow from operations is achieved.The controlling shareholder, Mr. Ng Hon Kin, previously borrowed $1,038,000 from seven individuals via promissory notes to finance IPO expenses and operating needs, which were later converted into Ordinary Shares.

Worse than expectedNet revenue decreased by 15.7% for the six months ended December 31, 2024, and by 24% for the fiscal year ended June 30, 2024.Net income for the fiscal year ended June 30, 2024, decreased significantly by 68%.The company reported negative cash flows from operating activities for both the recent six-month period and the last fiscal year.The company has substantial working capital deficits and a very low cash balance, leading auditors to express 'substantial doubt about its ability to continue as a going concern'.

Summary

MEDI Group Limited, a Cayman Islands holding company operating medical cosmetology and beauty services in Hong Kong under the 'Doctors Concept' brand, is pursuing an initial public offering (IPO) on the Nasdaq Capital Market.
The company aims to raise $15 million through the sale of 3,333,333 Class A Ordinary Shares, with an estimated IPO price between $4.00 and $5.00 per share.
Existing shareholders are also offering 4,272,222 Class A Ordinary Shares for resale, from which the company will not receive any proceeds.
Net revenue decreased by 15.7% to $3.25 million for the six months ended December 31, 2024, from $3.86 million in the prior year period.
Net income for the six months ended December 31, 2024, increased by 9.6% to $1 million, compared to $0.9 million in the prior year period.
For the fiscal year ended June 30, 2024, net revenue decreased by 24% to $6.11 million from $8.02 million in 2023.
Net income for the fiscal year ended June 30, 2024, significantly decreased by 68% to $0.61 million from $1.90 million in 2023, primarily due to increased audit fees and staff costs related to the offering.
The company reported negative operating cash flows of $611,480 for the six months ended December 31, 2024, and $1,031,834 for the year ended June 30, 2024.
Working capital deficits were substantial at $8,313,163 as of December 31, 2024, and $9,029,519 as of June 30, 2024, leading auditors to express substantial doubt about the company's ability to continue as a going concern.
The company plans to use IPO net proceeds for R&D capacity (5%), market expansion in new and existing geographical markets (25%), general working capital (65%), and advisory fee payment (5%).
MEDI Group operates a dual-class share structure, with Class B Ordinary Shares carrying 20 votes per share compared to Class A's one vote, ensuring concentrated control by Mr. Ng Hon Kin.
The company plans to close its Yuen Long shop by September 30, 2025, due to customer migration to mainland China service providers and intends to open a new shop elsewhere in Hong Kong.
Ms. Suzanne Chan will step down as CFO effective September 15, 2025, due to health reasons, and Ms. Kelly Sin Pui Ying will assume the role from that date.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including declining revenue, negative operating cash flows, and substantial working capital deficits, leading to a 'going concern' warning from auditors. While there are strategic plans for expansion and R&D, the current financial instability and high operational risks, particularly related to PRC regulatory uncertainty and market competition, outweigh the positives of customer retention and IPO proceeds. The dual-class share structure also limits public shareholder influence.

Positives

Net income for the six months ended December 31, 2024, increased by 9.6% to $1 million, demonstrating improved profitability in the short term despite revenue decline.
The company has a high customer retention rate, with approximately 2,600 customers holding unexpired prepaid packages, nearly 100% of whom are repeat customers.
MEDI Group has an established reputation for quality service, evidenced by the Enterprise Quality Service Award from INTACC in 2019 and recognition from Galderma as a Top Ten Sales Achievement Aesthetic Centre in Hong Kong for 2023 and 2024.
The company offers a broad range of beauty treatments and continuously introduces new procedures in response to technological advancements and market trends.
Management believes the recent operating results are temporary and expects profitability to grow as Hong Kong's economy recovers.

Negatives

Net revenue decreased by 15.7% for the six months ended December 31, 2024, and by 24% for the fiscal year ended June 30, 2024, indicating a significant downturn in business activity.
Net income for the fiscal year ended June 30, 2024, decreased substantially by 68% to $0.61 million, primarily due to increased audit fees and staff costs related to the IPO.
The company reported negative cash flows from operating activities for both the six months ended December 31, 2024 ($611,480) and the fiscal year ended June 30, 2024 ($1,031,834).
Significant working capital deficits of $8,313,163 as of December 31, 2024, and $9,029,519 as of June 30, 2024, raise substantial doubt about the company's ability to continue as a going concern.
The decline in revenue is attributed to weak economic conditions in Hong Kong, competition from Shenzhen due to RMB depreciation, and emigration of target customer base.
A substantial portion of total revenue (57.54% in FY2024, 66.71% in 6 months ended Dec 2024) comes from expired prepaid treatments, which could decrease if customers switch providers.
The company relies on a single medical practitioner, Dr. Pang Sai Yau, for medical aesthetic services, posing a key person risk.
The Yuen Long shop is being closed due to customer loss to mainland China service providers, indicating competitive pressure and market shifts.

Risks

The company's reputation is critical to its success, and negative publicity or undesirable treatment outcomes could cause significant harm.
Operating in a highly competitive industry with rapidly changing market trends, technological upgrades, and new injectables poses a risk to market share and profitability.
Demand for services is susceptible to changes in Hong Kong's economic conditions, as beauty and personal care services are discretionary items.
A lack of qualified employees, particularly beauty and personal care professionals and medical practitioners, could hinder growth plans and adversely affect operations.
The company could be held liable for malpractice of its medical practitioner and negligence of staff, with current insurance policies not covering all potential liabilities.
Regulations on the medical aesthetic services industry in Hong Kong may become increasingly stringent, leading to significant compliance costs and operational restrictions.
The independent registered public accounting firm has expressed substantial doubt about the company's ability to continue as a going concern due to negative cash flows and working capital deficits.
Failure to develop innovative services in a timely manner to meet changing customer preferences could adversely affect business and financial results.
Limited control over the quality of beauty equipment and treatment devices from suppliers could lead to customer complaints, claims, and operational disruptions.
Serious side effects from medical aesthetics procedures, though statistically insignificant, may occur, leading to legal proceedings, liabilities, and reputational damage.
Unfavorable public perception of the overall medical aesthetic services industry could lead to a decline in demand for the company's services.
The business has been materially and adversely affected by the COVID-19 pandemic, and another pandemic could have similar or worse impacts.
Reliance on the management team and key personnel, particularly Mr. Ng Hon Kin and Dr. Pang Sai Yau, means loss of their services could disrupt business.
The growth strategy, including geographical expansion and broadening service offerings, may not be successful or achieve expected results.
Failure to protect trade secrets and know-how or pursue infringement actions on intellectual properties could harm the business.
The system of internal control over financial reporting may have material weaknesses due to limited accounting personnel and resources.
Reliance on an internally designed database system (CARE) without timely backup and effective cybersecurity could adversely affect financial results and operations.
A downturn in the Hong Kong or global economy, or a change in economic and political policies of China, could materially and adversely affect business and financial condition.
Changes in Hong Kong government policies, regulations, rules, and law enforcement, which can be implemented quickly, could significantly impact profitability.
The PRC government may exercise significant oversight and discretion over Hong Kong businesses, potentially intervening in operations or disallowing the organizational structure, which could materially change operations or devalue shares.
Funds or assets in Hong Kong subsidiaries may not be available to fund operations or for other use outside of the PRC due to potential interventions or restrictions by the PRC government on cash transfers.
Becoming subject to scrutiny, criticism, and negative publicity involving U.S.-listed Chinese companies could harm business operations, the offering, and reputation, potentially leading to loss of investment.
Political risks associated with conducting business in Hong Kong, including changes in the relationship between the U.S., China, and Hong Kong, could adversely affect business.
Class A Ordinary Shares may be prohibited from trading in the United States under the HFCAA if the PCAOB is unable to inspect or investigate auditors located in Hong Kong for two consecutive years.
An active trading market for Class A Ordinary Shares may not be established or maintained, leading to reduced liquidity and price volatility.
The company does not expect to pay dividends in the foreseeable future, requiring investors to rely on price appreciation for returns.
Immediate and substantial dilution will be experienced by new investors purchasing Class A Ordinary Shares in this offering.
As an exempted company incorporated in the Cayman Islands and a foreign private issuer, the company is permitted to adopt certain home country corporate governance practices that differ from Nasdaq rules, potentially offering less protection to shareholders.
Shareholders may have more difficulties protecting their interests than they would as shareholders of a U.S. corporation due to differences in Cayman Islands law.
The stock price may be volatile and subject to rapid and substantial fluctuations unrelated to performance, especially given the relatively small public float and concentrated ownership.
If securities or industry analysts do not publish research or publish unfavorable or inaccurate research, the market price and trading volume could decline.
The sale or availability for sale of substantial amounts of Class A Ordinary Shares by existing shareholders could adversely affect the market price.
Short selling may drive down the market price of Class A Ordinary Shares, potentially leading to significant resource expenditure for defense against allegations.
Management has significant flexibility and discretion in using the net proceeds from the offering, and such uses may not produce income or increase share price.
More stringent criteria for emerging market companies by Nasdaq and U.S. regulators could add uncertainties to the offering, business operations, share price, and reputation.

Future Outlook

Management expects the recent operating results, characterized by revenue decline and negative cash flows, to be temporary, anticipating profitability growth as the Hong Kong economy recovers. The company plans to expand its geographical footprint, particularly in Southeast Asia, broaden service offerings to high-growth segments like male customers, upgrade and diversify existing services, and invest in R&D for new medical cosmetology devices and products. They also intend to recruit and train more beauty professionals and medical practitioners to support growth, aiming to restore the number of service centers to pre-COVID-19 levels.

Management Comments

"Our value proposition is that we deliver quality aesthetics solutions tailored to the unique needs of each customer at competitive prices."
"Our strategy is to differentiate ourselves by offering high-quality treatments and personalized services at a reasonable price instead of generic services at a discounted price."
"We believe that a public listing status will also enhance our corporate profile for the public and potential clients and investors."
"We believe our customer base is crucial for the success of any business expansion."
"We believe our loyal customer base is a result of our client-centric services."
"Our principal business objective is to strengthen our market position and expand our market share."
"We believe our expanded services will allow us to fully utilize our bigger network."
"We believe that with our extensive industry knowledge, we are ready to explore overseas markets with similar demographic, profiles and cultures."
"We believe training helps our employees improve their service performance, which ultimately increases their loyalty to the Company."
"We believe word of mouth is the most effective marketing channel, as returning customers may refer our services to their friends, family and work colleagues, and such referrals carry far greater weight to our target customers than paid advertisements."
"Providing quality non-surgical medical aesthetic services is one of our management priorities."
"We believe our cooperation with Dr. Pang allows us to remain competitive in the industry."
"Management has evaluated its available cash balance against its working capital requirements and believes that its capital resources are insufficient to maintain its business operations for the next twelve months."
"The Company is optimistic in generating sufficient operating cash flows to meet its working capital requirements for the year ended June 30, 2025, however the Company can be no assurance that the cost initiative will be continuously success and ensure the Company can generate sufficient operating cash flows for the next twelve months."

Industry Context

The global medical aesthetic services industry is projected to grow at an 11% CAGR from 2023 to 2028, driven by increased focus on personal appearance and demand for aesthetic procedures, particularly non-surgical ones. Hong Kong's beauty and personal care market is also expected to grow, albeit at a slower CAGR of 1.9% between 2024 and 2028. However, the company faces challenges from a weak Hong Kong economy, competition from mainland China due to currency depreciation, and emigration of its target customer base. The industry is highly competitive and fragmented, with increasing regulatory scrutiny and compliance costs. The company's strategy to focus on high-end medical aesthetic services and expand geographically aligns with broader industry trends towards specialized, quality treatments and market diversification.

Comparison to Industry Standards

The company's revenue decline of 24% for FY2024 and 15.7% for the six months ended December 31, 2024, contrasts with the projected global medical aesthetic services industry CAGR of 11% from 2023 to 2028, indicating underperformance relative to broader market growth.
The Hong Kong cosmetics market experienced a 38.6% decrease in 2023 from 2022, suggesting the company's revenue decline is partly attributable to a challenging local market, though its specific performance is still notable.
The company's reliance on 'expired treatments' for a significant portion of revenue (57.54% in FY2024) may indicate a less sustainable revenue model compared to competitors focused on active service redemption.
The company's high customer retention rate and focus on personalized, high-quality services align with strategies for differentiation in a competitive market, potentially positioning it well for future recovery.
The plan to expand into Southeast Asia (Malaysia and Singapore) targets markets with growing demand for high-end services, indicating a strategic move to diversify beyond the currently weak Hong Kong market, similar to other regional players seeking growth opportunities.
The company's auditors expressing 'substantial doubt about its ability to continue as a going concern' due to negative cash flows and working capital deficits is a significant red flag, indicating financial health below industry standards for a company seeking public listing.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Chief Financial Officer	Ms. Suzanne Chan	Ms. Kelly Sin Pui Ying	September 15, 2025	Ms. Suzanne Chan will step down due to health reasons.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Share Structure	Restructured into a dual-class share structure on March 19, 2025, consisting of Class A Ordinary Shares (1 vote/share) and Class B Ordinary Shares (20 votes/share).	March 19, 2025	Concentrates voting power with the Controlling Shareholder (Mr. Ng Hon Kin), who will own approximately 96.49% of total voting power post-IPO, making the company a 'controlled company' under Nasdaq rules and limiting influence of other shareholders.
Board Committees	Approved the establishment of an audit committee, a compensation committee, and a nomination committee, each operating pursuant to a charter upon effectiveness of the registration statement.	Immediately prior to completion of offering	Aims to comply with applicable requirements of the Sarbanes-Oxley Act, Nasdaq, and SEC rules, enhancing corporate oversight, though as a foreign private issuer, certain Nasdaq corporate governance requirements may be exempted.
Foreign Private Issuer Status	Qualifies as a foreign private issuer, eligible for reduced public company reporting requirements and exemptions from certain U.S. federal securities laws and Nasdaq corporate governance standards.	N/A	Provides flexibility in corporate governance but may afford shareholders less protection or information compared to U.S. domestic issuers. Risk of losing this status in the future could incur significant additional costs.
Code of Conduct and Ethics	Adopted a written code of business conduct and ethics applicable to directors, officers, and employees.	Immediately prior to completion of offering	Establishes ethical guidelines and standards for corporate behavior, enhancing internal controls and compliance.

Legal Proceedings

No pending claims, litigation, or other disputes as of December 31, 2024, that are likely to have a material adverse effect on the business, financial condition, or operations.
The company, its controlling persons, and associated medical practitioners are inevitably exposed to potential liability from complaints, claims, and litigation due to inherent health risks of services.
Dr. Pang Sai Yau, the medical partner, has agreed to indemnify the company against losses from customer complaints if found negligent, though this indemnification is of limited value and may not cover all losses.

Related Party Transactions

Mr. Ng Hon Kin, Chairman, CEO, and ultimate shareholder, controls Global Medical Equipment Co., Ltd., Smart Key International Consultant Co., Ltd., and Be Health Co., Ltd., which engage in transactions with the company.
Ms. Huang Weisi, a prior director, also controlled Euro Cos Co., Ltd., which had transactions with the company.
Mr. Ng Hon Kin assumed personal guarantees for the company's bank borrowings from Ms. Huang Weisi on April 2, 2024.
The company entered into a sub-lease agreement with Be Health Company Limited for a Yuen Long shop property, with rental fees paid in aggregate of $30,366 for the six months ended December 31, 2024, and $61,107 for the eleven months ended May 31, 2025.
Management fees were paid to Smart Key International Consultant Company Limited for administrative services, amounting to $14,817 for the six months ended December 31, 2024, and $39,527 for the eleven months ended May 31, 2025.
Equipment, materials, and services were purchased from Global Medical Equipment Co., Ltd. and Euro Cos Co., Ltd.
Mr. Ng Hon Kin's salary and employee benefits were paid by an associated company, amounting to $8,091 for the six months ended December 31, 2024, and $15,385 for the year ended June 30, 2024.
Promissory notes totaling $1,038,000 from seven individuals (including entities designated by noteholders like Many Trillion International Limited, Express Essential Holdings Limited, Able Talent Business Limited) were converted into Ordinary Shares on March 28, 2024.

Stakeholder Impact

**Shareholders (Existing & New):** Existing shareholders will experience dilution from the IPO. New investors face immediate and substantial dilution. The dual-class share structure significantly limits the voting power of Class A shareholders, concentrating control with Mr. Ng Hon Kin. The 'going concern' doubt poses a risk of complete loss of investment.
**Employees:** The company plans to recruit and train more beauty professionals and medical practitioners, indicating potential job growth and development opportunities. However, the closure of the Yuen Long shop may impact some employees.
**Customers:** The company aims to expand geographical footprints and broaden service offerings, potentially providing more accessible and diverse treatments. The closure of the Yuen Long shop might inconvenience customers in that area, but a new location is planned. High customer retention suggests satisfaction among existing clients.
**Suppliers & Creditors:** The company's liquidity issues and reliance on debt financing could pose risks to suppliers and creditors if financial conditions do not improve. Bank borrowings are personally guaranteed by Mr. Ng, offering some security.
**Regulatory Bodies:** The company is subject to ongoing scrutiny from SEC, PCAOB, and PRC/Hong Kong regulators, requiring significant compliance efforts and potentially facing sanctions if regulations are not met, especially concerning data security and overseas listings.

Next Steps

Complete the initial public offering and list Class A Ordinary Shares on the Nasdaq Capital Market under the symbol MEDG.
Set up research and development capacity, allocating approximately 5% of net IPO proceeds.
Penetrate and further expand into new and existing geographical markets, including Southeast Asia, allocating approximately 25% of net IPO proceeds.
Open new service centers to restore the network to pre-COVID-19 levels.
Close the Yuen Long shop by September 30, 2025, and open a new shop in another Hong Kong location.
Broaden service offerings to cater to high-growth segments, such as male customers, and introduce new skin care regimens.
Upgrade and broaden service offerings by monitoring advanced medical-grade equipment and developing new customized treatments.
Invest in software technology for real-time operational monitoring, centralized information exchange, and data analytics.
Recruit, train, and maintain a team of experienced management and senior beauty professionals, expanding the team to three medical practitioners and 40 therapists.
Ms. Kelly Sin Pui Ying will assume the role of Chief Financial Officer effective September 15, 2025.
The company will continue to monitor and analyze its cash flow position and ability to generate sufficient revenue sources.

Key Dates

Date	Description
2004-03-31	Grand Century Holding Company Limited (GCHL), the operating subsidiary, was founded in Hong Kong by Mr. Ng Hon Kin.
2006-06-21	Doctors Concept Medical and Cosmetics Company Limited (DCMCL) was incorporated as the trademarks custodian.
2012	A Steering Committee on Review of the Regulation of Private Healthcare Facilities was established in Hong Kong.
2013	The Report of the Working Group on Differentiation between Medical Procedures and Beauty Services was published, recommending certain procedures be performed by registered medical practitioners.
2013	Skin treatments using injections and energy-based processes became available to the mass market in Hong Kong.
2016	Body sculpturing treatments became available to the mass market in Hong Kong.
2018	Fat melting treatments became available to the mass market in Hong Kong.
2018-04-01	Hong Kong's two-tier profits tax rates regime became effective.
2018-11-15	The Private Healthcare Facilities Ordinance (PHFO) was passed in Hong Kong.
2019	The International Tax Co-operation (Economic Substance) Act (Revised) came into force in the Cayman Islands.
2019	MEDI Group was granted the Enterprise Quality Service Award by the International Aestheticians Chamber of Commerce (INTACC).
2019-12-19	Bank of China HKD2,000,000 Facility Letter dated.
2020-01-08	Start date for a HKD2,000,000 bank borrowing from Bank of China.
2020-03	The World Health Organization recognized the COVID-19 outbreak as a global pandemic, significantly disrupting the company's business.
2020-05-08	Start date for a HKD4,000,000 bank borrowing from Bank of China.
2020-06-30	The NPCSC adopted the Hong Kong National Security Law.
2020-12	The Holding Foreign Companies Accountable Act (HFCAA) became law.
2021-01-01	Section 10(1) of the PHFO came into operation for hospitals.
2021-06-10	The NPCSC enacted the PRC Data Security Law.
2021-06-22	The U.S. Senate passed the Accelerating Holding Foreign Companies Accountable Act (AHFCAA).
2021-07-01	GCHL adopted ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606).
2021-07-01	The company adopted ASU 2016-13, Financial Instruments – Credit Losses (Topic 326).
2021-07-06	The General Office of the Communist Party of China Central Committee and the General Office of the State Council jointly issued a document to crack down on illegal securities activities.
2021-08-20	The PRC Personal Information Protection Law was passed.
2021-08-30	Start date for a HKD2,000,000 bank borrowing from Bank of China.
2021-11-01	The PRC Personal Information Protection Law became effective.
2021-12	Ms. Leung Pik Ying (Dione) joined the Company as general manager.
2021-12-02	The SEC adopted amendments to finalize rules implementing the submission and disclosure requirements in the HFCAA.
2021-12-16	The PCAOB issued a determination that it was unable to inspect or investigate completely PCAOB-registered public accounting firms headquartered in mainland China and Hong Kong.
2021-12-28	Cybersecurity Review Measures were published by Cyberspace Administration of China (CAC) and other regulators.
2022-01-01	Section 10(1) of the PHFO came into operation for day procedure centers.
2022-01-04	The CAC issued revised measures to expand the types of businesses and circumstances that would require cybersecurity review.
2022-02-15	Cybersecurity Review Measures became effective.
2022-05-27	Start date for a HKD3,000,000 bank borrowing from Bank of China.
2022-07-07	CAC promulgated the Measures for the Security Assessment of Data Cross-border Transfer, effective September 1, 2022.
2022-08-26	The CSRC, MOF, and PCAOB signed a Statement of Protocol (Protocol) to allow PCAOB inspections.
2022-11	TAAD LLP, the company's auditor, was last inspected by the PCAOB.
2022-12-15	The PCAOB announced it secured complete access to inspect and investigate registered public accounting firms headquartered in mainland China and Hong Kong, vacating its previous determination.
2022-12-29	The AHFCAA was enacted, amending the HFCAA to reduce the non-inspection period from three years to two.
2023-02-17	The CSRC promulgated the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies (New Overseas Listing Rules).
2023-03	COVID-19 pandemic measures were lifted in Hong Kong.
2023-03-31	New Overseas Listing Rules came into effect.
2023-05-30	Lease start date for Kwong Wah Plaza, Yuen Long shop.
2023-07-17	Mr. Ng Hon Kin began borrowing from individuals via promissory notes to finance IPO and operations.
2023-08-01	Mr. Ng Hon Kin served as a director of DCMCL.
2023-08-15	Provisional estimate of Hong Kong population released by CSD.
2023-08-20	Lease start date for Langham Place shop.
2023-10	End of period for promissory notes issued by Mr. Ng Hon Kin.
2023-10-16	Lease Contract dated between Grand Century Holding Company Limited and Renaissance City Development Company Limited.
2023-12	FASB issued ASU 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures.
2024-02-08	End date for Mr. Ng Hon Kin borrowing from individuals via promissory notes.
2024-03-13	MEDI Group Limited was incorporated in the Cayman Islands.
2024-03-15	Mr. Ng Hon Kin served as a director of MTHL.
2024-03-19	Company's share structure was restructured into a dual-class structure; Ordinary Shares reclassified to Class A and Class B Ordinary Shares.
2024-03-21	MEDI Trade Holding Limited (MTHL) was incorporated in Hong Kong.
2024-03-22	MEDI Trade Corporation Limited (MTL) was incorporated in Hong Kong.
2024-03-28	The Group completed its Reorganization, consolidating business operations into an offshore holding structure.
2024-03-28	Promissory notes issued by Mr. Ng Hon Kin were cancelled, and Ordinary Shares were issued to noteholders' designated entities.
2024-03-28	Mr. Ng Hon Kin served as a director of MTL.
2024-04-01	Lease Contract dated between Smart Key International Consultant Company Limited and Edward Wong Development Company Limited.
2024-04-01	Lease Contract dated between Grand Century Holding Company Limited and Edward Wong Development Company Limited.
2024-04-02	Mr. Ng assumed Ms. Huang Weisi's personal guarantees for bank loans.
2024-06-24	Lease Contract dated between Grand Century Holding Company Limited and Sun Hong Kai Real Estate (Sales and Leasing) Agency Limited.
2024-07-12	Lease start date for World Trade Centre shop.
2024-07-29	Cooperation Agreement between Be Health Company Limited and GCHL dated.
2024-07-30	Lease Contract dated between Smart Key International Consultant Company Limited and Strong Goal Investments Limited.
2024-07-31	Management Agreement between Smart Key International Consultant Company Limited and Grand Century Holding Company Limited dated.
2024-08-01	Lease start date for CEO Tower office.
2024-08-03	Lease start date for Office No. 6-7, 8/F, Kwong Wah Plaza, Yuen Long (sub-leased).
2024-08-15	Ms. Kelly Sin Pui Ying was appointed as the new Chief Financial Officer.
2024-08-26	Mr. Ng entered into agreements to assume all current accounts of related parties.
2024-08-30	China's State Council approved the Regulations on Network Data Security Management.
2024-09-01	The company moved to its new office location at Unit 15-16, 22/F., CEO Tower, 77 Wing Hong Street, Cheung Sha Wan, Kowloon, Hong Kong.
2025-01-01	Regulations on Network Data Security Management will take effect.
2025-09-15	Ms. Suzanne Chan will step down as CFO, and Ms. Kelly Sin Pui Ying will assume the role.
2025-09-30	Planned closure date for the Yuen Long shop.
2025-12-15	Effective date for ASU 2023-09 Income Taxes (Topic 740) for public business entities.
2026-05-29	Lease end date for Kwong Wah Plaza, Yuen Long shop (both units).
2027-06-30	Contingent effective date for ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SECs Disclosure Update and Simplification Initiative.
2027-07-11	Lease end date for World Trade Centre shop.
2027-07-31	Lease end date for CEO Tower office.
2028	Global medical aesthetic services industry projected to reach US$15,304 million, growing at a CAGR of 11% from 2023.
2028	Hong Kong non-medical aesthetic market expected to grow to US$2,480.99 million from US$1,997.89 million in 2018.
2028	Hong Kong beauty and personal care market projected to grow at a CAGR of 1.9% between 2024 and 2028.
2028	Skincare segment in Hong Kong projected to grow at a CAGR of 1.81% between 2024 and 2028.
2030-05-07	Maturity date for a HKD4,000,000 bank borrowing from Bank of China.
2031-08-29	Maturity date for a HKD2,000,000 bank borrowing from Bank of China.
2032-05-26	Maturity date for a HKD3,000,000 bank borrowing from Bank of China.

Recommendation

strong sell

The filing reveals severe financial distress, including substantial working capital deficits, negative operating cash flows, and a 'going concern' warning from auditors. While the IPO aims to raise capital, the company's historical revenue decline (24% in FY2024) and significant drop in net income (68% in FY2024) indicate fundamental operational challenges exacerbated by macroeconomic factors and competition. The reliance on 'expired treatments' for a large portion of revenue is unsustainable. Furthermore, the dual-class share structure grants disproportionate control to the CEO, limiting public shareholder influence. The numerous regulatory and political risks associated with operating in Hong Kong under PRC oversight add significant uncertainty. Given these profound financial and operational weaknesses, coupled with the 'going concern' doubt, the stock presents an extremely high-risk investment with a strong likelihood of significant capital loss.

Keywords

Medical Cosmetology, Beauty Services, Hong Kong, SEC Filing, IPO, Nasdaq, F-1/A, Financial Performance, Risk Factors, Corporate Governance, Dual-Class Shares, Going Concern, Market Expansion, Regulatory Risk, China-Hong Kong Relations, PCAOB, HFCAA, Cosmetics Industry

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.